The oncolytic peptide LTX-315, which has been de novo designed based on structure-activity relationship studies of host defense peptides, has the ability to kill human cancer cells and …

2016年4月15日 · LTX-315 is a first-in-class oncolytic peptide-based local immunotherapy that meets these criteria by inducing a type of malignant cell death that elicits anticancer immune …

2024年11月27日 · 通过破坏癌细胞的质膜和增加线粒体膜的通透性，ltx-315能够迅速诱导癌细胞死亡，并释放信号分子吸引免疫系统中的t细胞至肿瘤部位，进一步清除残留的肿瘤细胞。

2016年3月10日 · LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase …

2022年6月14日 · LTX-315 (K-K-W-W-K-K-W-Dip-K-NH 2), a novel synthetic anticancer peptide, has the potential to adopt an amphipathic helical coil structure and was designed for …

本研究旨在证明 LTX-315 在 PD-L1 抑制诱导的抗胰腺癌免疫中的潜在作用和机制。 方法 免疫缺陷和免疫活性小鼠模型均用于评估单一疗法和联合疗法的治疗效果。 流式细胞术和免疫组织化 …

2014年6月25日 · We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete …

2017年5月11日 · The oncolytic peptide LTX-315, which has been de novo designed based on structure–activity relationship studies of host defense peptides, has the ability to kill human …

2021年8月10日 · LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer …

2025年3月3日 · LTX-315@ZIF-8 NPs exhibited potent cytotoxicity against cancer cells. The serum stability experiment and time-inhibition curve assay indicated that ZIF-8 NPs could …